New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
作者： Sébastien Albert , Maria Serova , Chantal Dreyer , Marie-Paule Sablin , Sandrine Faivre
DOI: 10.1517/13543784.2010.499121
关键词: TOR Serine-Threonine Kinases 、 Signal transduction 、 RPTOR 、 Hsp90 、 mTORC1 、 Allosteric regulation 、 Chemistry 、 Protein kinase B 、 Cell biology 、 PI3K/AKT/mTOR pathway
摘要: Importance of the field: Contrasting with broad activation PI3K/AKT/mammalian target rapamycin (mTOR) survival pathway in most cancer, activity rapalogues appears to be restricted a few tumor types.Areas covered this review: The analysis molecular PI3K/AKT/mTOR and resistance mechanisms led development several inhibitory molecules.What reader will gain: New anticancer agents including PI3K inhibitors, dual PI3K/mTOR specific mTOR AKT inhibitors may have direct effects on targets by competing ATP or non-ATP-competitive allosteric modulators protein functions. In addition, another way blocking abnormal achieved using HSP90 inhibitors. paper we review novel drugs inhibiting signaling pathway.Take home message: Several trials are ongoing targeting key kinases involved m...
informahealthcare.com参考文章(82)
G. Shapiro, E. Kwak, J. Baselga, J. Rodon, C. Scheffold, A. D. Laird, C. Bedell, G. Edelman, Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors Journal of Clinical Oncology. ,vol. 27, pp. 3500- 3500 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.3500
E K-H Han, J D Leverson, T McGonigal, O J Shah, K W Woods, T Hunter, V L Giranda, Y Luo, Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition Oncogene. ,vol. 26, pp. 5655- 5661 ,(2007) , 10.1038/SJ.ONC.1210343
Zhihong Zeng, Dos D. Sarbassov, Ismael J. Samudio, Karen W. L. Yee, Mark F. Munsell, C. Ellen Jackson, Francis J. Giles, David M. Sabatini, Michael Andreeff, Marina Konopleva, Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML Blood. ,vol. 109, pp. 3509- 3512 ,(2007) , 10.1182/BLOOD-2006-06-030833
Karen G. Chee, Jeff Longmate, David I. Quinn, Gurkamal Chatta, Jacek Pinski, Przemyslaw Twardowski, Chong-Xian Pan, Angelo Cambio, Christopher P. Evans, David R. Gandara, Primo N. Lara, The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clinical Genitourinary Cancer. ,vol. 5, pp. 433- 437 ,(2007) , 10.3816/CGC.2007.N.031
Jeffrey A. Engelman, Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nature Reviews Cancer. ,vol. 9, pp. 550- 562 ,(2009) , 10.1038/NRC2664
P Cao, S-M Maira, C García-Echeverría, D W Hedley, Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts British Journal of Cancer. ,vol. 100, pp. 1267- 1276 ,(2009) , 10.1038/SJ.BJC.6604995
Dos D Sarbassov, Siraj M Ali, Shomit Sengupta, Joon-Ho Sheen, Peggy P Hsu, Alex F Bagley, Andrew L Markhard, David M Sabatini, None, Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular Cell. ,vol. 22, pp. 159- 168 ,(2006) , 10.1016/J.MOLCEL.2006.03.029
Neil E. Torbett, Antonio Luna-Moran, Zachary A. Knight, Andrew Houk, Mark Moasser, William Weiss, Kevan M. Shokat, David Stokoe, A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochemical Journal. ,vol. 415, pp. 97- 110 ,(2008) , 10.1042/BJ20080639
Sandrine Faivre, Guido Kroemer, Eric Raymond, Current development of mTOR inhibitors as anticancer agents Nature Reviews Drug Discovery. ,vol. 5, pp. 671- 688 ,(2006) , 10.1038/NRD2062
Christopher W. Ryan, Jacqueline Vuky, Joseph S. Chan, Zunqiu Chen, Tomasz M. Beer, Deirdre Nauman, A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. Investigational New Drugs. ,vol. 29, pp. 374- 379 ,(2011) , 10.1007/S10637-009-9365-Y